GB Sciences, Inc. (GBLX)
Stock Price:
$0.0307 USD
0.0007 (2.33%)
Updated Aug 11, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
8.37M |
| Revenue (ttm) |
3.06M |
| Net Income (ttm) |
-8.73M |
| Shares Out |
272.77M |
| EPS (ttm) |
-0.05 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$0.0307 |
| Previous Close |
$0.0300 |
| Change ($) |
0.0007 |
| Change (%) |
2.33% |
| Day's Open |
0.0307 |
| Day's Range |
0.0285 - 0.0320 |
| Day's Volume |
323,937 |
| 52-Week Range |
0.0151 - 0.1440 |
More Stats
| Market Cap |
8.37M |
| Enterprise Value |
16.17M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
272.77M |
| Float |
247.01M |
| EPS (basic) |
1344473.94 |
| EPS (diluted) |
-0.05 |
| FCF / Share |
-0.03 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2.73 |
| PB Ratio |
1.08 |
| Revenue |
3.06M |
| Operating Income |
-11.36M |
| Net Income |
-8.73M |
| Free Cash Flow |
-6.88M |
| Net Cash |
-7.80M |
| Net Cash / Share |
-0.03 |
| Gross Margin |
6.81% |
| Operating Margin |
-370.82% |
| Profit Margin |
-378.40% |
| FCF Margin |
-224.72% |
| ROA |
-31.75% |
| ROE |
-75.01% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 3.45 | 2.51 | - | - | - | - | - |
| Revenue Growth | 37.61% | - | - | - | - | - | - |
| Gross Profit | 0.21 | 1.73 | - | - | - | - | - |
| Operating Income | -15.59 | -17.82 | -8.93 | -6.96 | -7.97 | -0.19 | -0.11 |
| Net Income | -23.65 | -22.97 | -9.91 | -6.77 | -7.72 | -0.66 | 0.04 |
| Shares Outstanding | 210 | 133 | 79.00 | 44.91 | 29.52 | 0.94 | 0.97 |
| Earnings Per Share | -0.13 | -0.17 | -0.13 | -0.15 | -0.26 | -0.70 | 0.04 |
| Operating Cash Flow | -9.24 | -12.25 | -4.47 | -3.56 | -3.50 | -0.36 | -0.04 |
| Capital Expenditures | -10.58 | -3.43 | -3.05 | -0.88 | -0.94 | -0.02 | - |
| Free Cash Flow | -19.82 | -15.68 | -7.52 | -4.45 | -4.44 | -0.38 | -0.04 |
| Cash & Equivalents | 0.18 | 3.58 | 2.69 | 0.03 | 0.00 | 0.34 | 0.34 |
| Total Debt | 6.12 | 7.55 | 3.93 | 2.61 | 0.18 | 1.27 | 1.27 |
| Net Cash / Debt | -5.94 | -3.97 | -1.24 | -2.58 | -0.18 | -0.93 | -0.93 |
| Assets | 30.02 | 24.05 | 13.01 | 2.44 | 1.45 | 0.54 | 0.54 |
| Liabilities | 12.87 | 8.42 | 4.60 | 4.41 | 3.38 | 1.55 | 1.55 |
| Book Value | 8.30 | 12.75 | 8.33 | -1.90 | -1.68 | -1.01 | -1.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
GB Sciences, Inc. |
| Country |
United States |
| Employees |
56 |
| CEO |
John Claybron Poss |
Stock Information
| Ticker Symbol |
GBLX |
| Stock Exchange |
US OTC |
| Unique Identifier |
OTCMKTS: GBLX |
Description
GB Sciences, Inc. focuses to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for various ailments. It is developing technologies in plant biology, cultivation and extraction techniques, which are combined with biotechnology; and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.